新聞中心
關注我們
11 Mar
2019

全球性流感帶動醫療需求知臨集團把握機遇創造價值

<中國財經觀察網>

  2018年年初,一篇名為《流感下的北京中年》的文章登上微博熱搜、刷屏微信朋友圈。人們在感慨生命脆弱的同時,也開始更加重視流感等傳染疾病的防治。在健康需求上升和科學技術發展的雙重趨勢下,運用先進科技探索未知領域,依靠技術發展滿足人類需求,已成為知臨集團(NASDAQ: APM)等眾多醫藥科研機構的共同目標。

  全球性流感引發廣泛關注 知臨首創抗流感藥物展現價值

國家衛健委近日發布的《2019年1月全國法定傳染病疫情概況》顯示,2019年1月份我國流行性感冒發病數為60.85萬例,死亡143人,已超過2017年全年報告流感死亡人數的三倍,約與2018年全年報告死亡人數相當。此外,根據印度國家疾病控制中心公佈的數據,印度2019年以來已確診超過1.2萬例甲型H1N1流感病例,其中377人死亡。而法國公共衛生部門2月20日發布的流感疫情監測報告也顯示,2018年10月1日至2019年2月3日,法國流感疫情已造成約2800人死亡。全球性的流感疫情已經引發人們越來越多的關注。

  研究結果表明,每年流感爆發導致約3至5百萬宗嚴重的流感病毒感染病例,引致29至65萬宗死亡個案,其中50%到80%的病例是都是由甲型流感引起的。針對全球範圍內高傳染性、高發病率、並發症嚴重的流行性感冒,香港知臨集團通過深入的研究和探索,首創了針對核蛋白的新型抗流感候選小分子ALS-1。這種新型抗流感小分子藥物能抑制常見的H1N1病毒、H3N2亞型和H5N1病毒,可以有效治療甲型流感病毒引起的病毒性感染。此外,ALS-1作用於核蛋白這一獨特的靶點,也使其與所有目前市場上存在耐藥性問題的抗甲型流感病毒藥物區別開來。這份成果不僅代表著醫療史上一項重要發現,對流行性感冒的防治具有特殊意義,更展現出廣闊的市場空間和良好的發展前景。據預測,2025年全球流感藥物市場規模預期將達到12億美元,知臨集團的研究成果如在未來得到推廣應用,不僅能填補人類傳染病醫療技術上的空白,也將同時創造極高的商業價值。

  探索傳染病非抗生素療法 開創免疫治療新紀元

  除了針對甲型流感的藥物研究外,知臨集團一直關注各類傳染病及常見病的預防和治療,其重要科研項目還包括抗“超級細菌”的藥物研究等。 “超級細菌”的原名為耐甲氧西林金黃色葡萄球菌(MRSA),是由於抗生素的濫用使金黃葡萄球菌不斷變異、演化出抗藥性所產生惡性細菌。金黃葡萄球菌廣泛分佈在空氣、土壤、水源中,是一類十分常見的病菌。據研究結果統計,全球約有5,300萬人為金黃色MRSA帶菌者。在美國,每年約有126,000人因此類細菌的感染住院,其中約有94,000人發生嚴重感染,並且導致大約19,000人死亡。

在探索能抵禦“超級細菌”的藥物的過程中,由於MRSA已經對大部分現有的抗生素藥物產生了耐藥性,知臨集團便與香港大學合作共同研發了對抗“超級細菌”的新型非抗生素合成抑製劑ALS-4。這是化學遺傳學第一次被嘗試用來解決MRSA感染問題。這一革命性的理念和化學遺傳學應用的發現,構成了發現ALS-4的基礎,在瑞士日內瓦第四屆國際預防和感染控制會議(ICPIC 2017)上榮獲學術創新一等獎,獲得科學界的高度認可。 ALS-4小分子藥物可抑制用來保護金黃色葡萄球菌的金黃色素的產生而不殺死細菌,進一步使得免疫系統能夠清除MRSA。未來,隨著後抗生素時代的發展變化,如果這項研究成果成功落地並商品化,將標誌著全人類依賴抗生素的舊時代會徹底改變。

  成功登陸納斯達克資本市場 募集資金用於未來醫療研究

  醫學革命更迭總是源於人類的新需求,在健康需求不斷提高、技術發展日趨快速的背景下,知臨集團始終致力於探索醫學的空白領域。事實上,知臨集團涉獵醫藥與非醫藥兩個板塊,除了抗甲型流感、抗MRSA的藥物研究外,也潛心研發適用於不同領域的候選藥品及候選醫療器械。截至2017年底,知臨集團已經在腦神經、傳染病、胃腸病、腫瘤和自然健康等領域取得11項專利技術的獨家授權,在手術機器人(19.54 +0.10%,診股)、優越醫療服務等非醫藥領域也享有豐厚的研究成果。

  為了未來更深入的研究以及成果的推廣應用,知臨集團在深耕學術領域的同時也積極探索著資本市場發展途徑。 2018年9月,知臨集團披露招股書併申請於美股納斯達克市場上市。經過多地路演及深入的機構交流,知臨集團得到平安保險及安德思資產管理(香港)有限公司合資成立的私募基金安德思平安機會基金及一眾投資者支持,並於美國東部時間12月18日在納斯達克全球市場正式開始交易。

  知臨集團本次公開發售以每股15.80美元的價格發行了761,419股A類普通股,在不扣除承銷商折扣、佣金以及其他發行費用的情況下,此次發售共籌集到12,030,420美元。據了解,本次募集資金將用於開發針對流感治療的ALS-1項目、針對MRSA的ALS-4項目以及治療子宮內膜異位症的NLS-1項目。預計未來,知臨集團將通過更加深入的研究和探索,開發各類創新醫學治療應用,在滿足人類醫療需求的同時不斷創造商業投資價值。

17 Dec
2018

知臨集團宣布完成首次公開募股

<BUSINESS WIRE>
(新聞只有英文版本)

Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the offering were $12,030,420, before deducting underwriting discounts and commissions and other offering expenses. While certain selling shareholders are offering to resell up to 1,595,235 Class A Ordinary Shares subject to certain lock-up periods, as applicable, none of the gross proceeds of the IPO will be used to purchase the selling shareholders’ securities nor will the Company receive any proceeds from the selling shareholders’ resale. The shares are expected to commence trading on The NASDAQ Global Market on December 18, 2018 at any time between 11:00 a.m. to 12:00 p.m. ET, under the ticker symbol “APM.”

Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited acted as co-underwriters for the offering.

A registration statement has been filed with the SEC and became effective on December 3, 2018. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Boustead Securities, LLC, email: offerings@boustead1828.com or by calling +1 (949) 502-4409 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 265, Irvine, CA 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aptorum Group Limited

We are a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. We have obtained exclusive licenses for our technologies. In addition, we are also developing certain proprietary technologies as product candidates. We are pursuing therapeutic and diagnostic projects (including projects seeking to use extracts or derivatives from natural substances to treat diseases) in neurology, infectious diseases, gastroenterology, oncology and other disease areas. We also have projects focused on surgical robotics. In addition, we opened a medical clinic, AML Clinic, in June 2018. Its initial focus is on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population. For more information about the Company, please visit www.aptorumgroup.com.

About Boustead Securities, LLC

Boustead Securities, LLC ("Boustead") is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead's core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information, visit www.boustead1828.com.

About China Renaissance Securities (Hong Kong) Limited

China Renaissance (“CR”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally. CR has offices in Beijing, Shanghai, Hong Kong and New York, with approximately 600 employees. As of March 31, 2018, CR had advised on approximately 700 transactions worth over US$100 billion since the inception, and CR had AUM of approximately US$4.1 billion in new economy investments. For more information, visit www.huaxing.com.

About AMTD Global Markets Limited

AMTD Global Markets Limited (“AMTD”) is a Hong Kong-based comprehensive financial institution dedicated to serving and bridging capital and resources across mainland China, Hong Kong and the globe. As one of the largest Hong Kong-based non-bank financial institution, AMTD has been widely recognized as a pre-eminent capital markets player with leading cross-border investment banking capabilities in Asia. Founded in 2003, AMTD has a long history of promoting technological innovations and the development of New Economy sectors, especially in the fields of FinTech, Artificial Intelligence and Healthcare. For more information, visit www.amtdgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding listing on the NASDAQ Global Market and the completion of the IPO are forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, risks and uncertainties related to the satisfaction of the customary closing conditions related to the IPO and the listing on NASDAQ. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof unless required by the applicable laws, regulations or rules.

Contacts
At the Company:
Sabrina Khan, CFO
Aptorum Group Limited
Phone: +852 2117 6611
Email: investor.relations@aptorumgroup.com

×
×
×
×
使用條款

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.